Serpin E1/PAI-1 Monoclonal Antibody(Capture)

catalog number: AN001460P



Note: Centrifuge before opening to ensure complete recovery of vial contents.

| - | | | | | | |
|---|--------------|----|-----|----|----|---|
| | es | OF | ч г | 71 | IA | m |
| ய | \mathbf{c} | UI | ш. | յս | ΙU | ш |

Reactivity Human

Immunogen Recombinant Human Serpin E1/PAI-1 Protein expressed by Mammalian

HostRatIsotypeRat IgG2aClone10F2

Purification Protein A/G Purification


Conjugation Unconjugated

buffer Phosphate buffered solution, pH 7.2, containing 0.05% proclin 300.

Applications Recommended Dilution

ELISA Capture 2-8 μg/mL

Data



Sandwich ELISA-Recombinant Human Serpin E1/PAI-1

Protein standard curve. Background subtracted standard curve

using Serpin E1/PAI-1 antibody(AN001460P)

(Capture), Serpin E1/PAI-1 antibody(AN001470P)(Detector)

in sandwich ELISA. The reference range value for

Recombinant Human Serpin E1/PAI-1 Protein is 0.15625-10

ng/mL.

Preparation & Storage

Storage Storage Store at 4°C valid for 12 months or -20°C valid for long term storage, avoid freeze /

thaw cycles.

Shipping The product is shipped with ice pack, upon receipt, store it immediately at the

temperature recommended.

Background

For Research Use Only

Serpin E1/PAI-1 Monoclonal Antibody(Capture)

catalog number: AN001460P



Plasminogen activator inhibitor 1,also known as PAI-1,Endothelial plasminogen activator inhibitor,SerpinEl and PlANH 1, is a secreted glycoprotein that belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis. Defects in SerpinEl are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinEl defect in the plasma. High concentrations of SerpinEl have been associated with thrombophilia which is an autosomal dominant disorder in which affected individuals are prone to develop serious spontaneous thrombosis. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins, which is based on a metastable native state becoming stabilised by insertion of the RCl into the central beta-sheet A and formation of covalent complexes with target proteases. Greater expression of PAI-1 has been associated with increased survival of cells and resistance to apoptosis. PAI-1 appears to influence apoptosis by decreasing cell adhesion (anoikis) as well as its effect on intracellular signaling. PAI-1, in its active state also binds to the extracellular protein vitronectin. When in complex with its target proteases, it binds with high affinity to endocytosis receptors of the low density receptor family. The mechanisms of PAI-1 overexpression during obesity are complex and it is conceivable that several inducers are involved at the same time at several sites of synthesis. PAI-1 is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis.